$1.77
0.86% today
Nasdaq, Sep 03, 04:50 pm CET
ISIN
NL0012661870
Symbol
IFRX

InflaRx N.V. Stock price

$1.75
+0.86 96.98% 1M
+0.50 40.00% 6M
-0.72 29.15% YTD
+0.16 10.06% 1Y
-0.55 23.91% 3Y
-2.45 58.33% 5Y
-13.24 88.33% 10Y
-13.24 88.33% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.15 9.38%
ISIN
NL0012661870
Symbol
IFRX
Industry

Key metrics

Basic
Market capitalization
$117.5m
Enterprise Value
$62.3m
Net debt
positive
Cash
$55.9m
Shares outstanding
67.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
618.3 | 1,381.8
EV/Sales
328.1 | 733.2
EV/FCF
negative
P/B
1.8
Financial Health
Equity Ratio
80.8%
Return on Equity
-75.0%
ROCE
-89.1%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$190.0k | $85.0k
EBITDA
$-58.9m | $-1.4m
EBIT
$-59.4m | $-63.9m
Net Income
$-52.7m | $-53.0m
Free Cash Flow
$-50.3m
Growth (TTM | estimate)
Revenue
58.3% | -55.3%
EBITDA
2.3% | 97.7%
EBIT
2.5% | -3.6%
Net Income
3.4% | 1.3%
Free Cash Flow
0.1%
Margin (TTM | estimate)
Gross
-1,331.5%
EBITDA
-31,002.2% | -1,676.0%
EBIT
-31,278.6%
Net
-27,752.3% | -62,293.1%
Free Cash Flow
-26,450.4%
More
EPS
$-0.8
FCF per Share
$-0.7
Short interest
1.4%
Employees
74
Rev per Employee
$0.0
Show more

Is InflaRx N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

InflaRx N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a InflaRx N.V. forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a InflaRx N.V. forecast:

Buy
86%
Hold
14%

Financial data from InflaRx N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.19 0.19
58% 58%
100%
- Direct Costs 6 6
369% 369%
3,158%
-2.53 -2.53
118% 118%
-1,332%
- Selling and Administrative Expenses 24 24
6% 6%
12,563%
- Research and Development Expense 38 38
1% 1%
19,768%
-59 -59
2% 2%
-31,000%
- Depreciation and Amortization 0.53 0.53
16% 16%
279%
EBIT (Operating Income) EBIT -59 -59
2% 2%
-31,277%
Net Profit -53 -53
3% 3%
-27,753%

In millions USD.

Don't miss a Thing! We will send you all news about InflaRx N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

InflaRx N.V. Stock News

Neutral
GlobeNewsWire
13 days ago
JENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2025. Details are as follows:
Neutral
GlobeNewsWire
27 days ago
JENA, Germany, Aug. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the three months ended June 30, 2025, and provided a business update.
Neutral
GlobeNewsWire
about one month ago
JENA, Germany, July 31, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2025 financial and operating results on August 7, 2025, before the market opens. No conference call is planned.
More InflaRx N.V. News

Company Profile

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

Head office Netherlands
CEO Niels Riedemann
Employees 74
Founded 2007
Website www.inflarx.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today